Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

Delayed Quote. Delayed  - 09/28 04:24:26 pm
18450 ILa   -1.91%
09/26 TEVA PHARMACEUT : Shareholders sue Teva over Rimsa acquisition
09/23 TEVA PHARMACEUT : TEVA) Unveils Successful AIM-TD Clinical Trial Res..
09/22DJTEVA PHARMACEUT : Huntington Disease Drug Meets Primary Endpoint
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Teva Asks FDA Not to Approve New MS Drugs Till Advisers Evaluate Safety

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/09/2013 | 09:09pm CEST
   By Peter Loftus 
 

Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)), which sells the blockbuster multiple-sclerosis drug Copaxone, has asked the U.S. Food and Drug Administration not to approve any new MS drugs until their safety risks have been evaluated by outside advisers.

Teva's petition is aimed at Biogen Idec Inc. (>> Biogen Idec Inc.), which expects an FDA decision by late March on Biogen's application to market a new MS treatment, known as BG-12, an orally administered pill that analysts expect will be a formidable competitor to the injected Copaxone.

In a Dec. 31 citizen petition to the FDA, Teva asked the agency not to approve any new MS drugs until the agency refers them to an advisory committee for evaluation. Advisory committees sometimes review new drug applications to provide guidance to the agency.

Teva said it was important for the agency to hear outside advisers' evaluations of any safety risks, in light of risks that have emerged after MS treatments were approved in recent years, including Biogen's own Tysabri MS treatment. Tysabri was removed from the market soon after its 2004 introduction after some recipients experienced a serious brain infection, and reintroduced in 2006 with a patient-monitoring plan.

Teva said in its petition that BG-12 "may be associated with other serious safety risks" including the potential risk for kidney-related problems.

Teva cited a publicly accessible website containing animal toxicology data suggesting that kidney changes were seen in animals after they received BG-12's active ingredient, dimethyl fumarate, in studies. The website stated that the relevance of these findings to humans isn't known, according to the Teva petition.

Biogen spokeswoman Kate Niazi-Sai said the company is confident in the clinical data supporting BG-12's safety and efficacy, and the regulatory review appears to be on track.

Results of a late-stage clinical trial of BG-12 published last year in the New England Journal of Medicine showed the incidence of kidney-related adverse events was similar between those receiving BG-12 and those on a placebo. There were no cases of kidney failure classified by researchers as serious adverse events, according to the article.

RBC Capital Markets analyst Shibani Malhotra, who reported the Teva citizen petition in a research note earlier Wednesday, said it may not pose a big obstacle for BG-12's approval because a similar drug has been available as a psoriasis treatment in Europe, and serious safety issues haven't emerged.

RBC analyst Michael Yee said he still expects the FDA to approve BG-12 by the targeted action date in late March.

On Monday at the J.P. Morgan Healthcare conference in San Francisco, Biogen Chief Executive George Scangos defended the experimental MS pill. He acknowledged there has been some chatter about BG-12 safety, but chalked this up to competitors marketing against the product.

"We're very confident in the safety," he said. "I kind of take it as a compliment that the competition is worried about BG-12."

Teva spokeswoman Denise Bradley said the petition was intended to bring to light important points "to protect the safety of patients." Teva wants to ensure "that appropriate safeguards are implemented to maintain an acceptable risk-benefit profile" for any new MS drug, she said.

FDA spokeswoman Sandy Walsh said the agency will review the petition.

--Jon Kamp contributed to this article.

-Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
09/26 TEVA PHARMACEUTICAL INDUSTRIES : Shareholders sue Teva over Rimsa acquisition
09/23 TEVA PHARMACEUTICAL INDUSTRIES LTD. : TEVA) Unveils Successful AIM-TD Clinical ..
09/22DJTEVA PHARMACEUTICAL INDUSTRIES : Huntington Disease Drug Meets Primary Endpoint
09/22 TEVA PHARMACEUTICAL INDUSTRIES : Announces Positive Top-Line Data from Second Ph..
09/21DJMylan CEO Faces Tough Questioning in EpiPen Hearing
09/21 MYLAN : shares languish at low valuation as EpiPen hearing nears
09/20 REGENERON PHARMACEUTICALS : Teva buys rights to Regeneron chronic pain drug for ..
09/20 TEVA PHARMACEUTICAL INDUSTRIES : and Regeneron Announce Global Collaboration to ..
09/20 TEVA PHARMACEUTICAL INDUSTRIES : Regeneron and Teva Announce Global Collaboratio..
09/19 TEVA PHARMACEUTICAL INDUSTRIES : Announces Results from Exploratory 52-Week Phas..
More news
Sector news : Pharmaceuticals - NEC
02:13p Monsanto ally Novozymes sees opportunity, risk in Bayer merger
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:46a Teva launches generic Epzicom in U.S.
09/27 A Sudden Abundance Of Warning Signs
09/25 TEVA : Buy For Today's Value And Tomorrow's Growth
09/23 SNIPPET ROUNDUP : Firsts For Chinese CAR Companies, Setbacks For J&J And Mast
09/22 In Teva, Regeneron Finds Its Sanofi For Pain
Advertisement
Financials ($)
Sales 2016 22 447 M
EBIT 2016 7 361 M
Net income 2016 3 321 M
Debt 2016 25 666 M
Yield 2016 2,31%
P/E ratio 2016 11,51
P/E ratio 2017 9,50
EV / Sales 2016 3,41x
EV / Sales 2017 2,75x
Capitalization 50 907 M
More Financials
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 68,0 $
Spread / Average Target 35%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Erez Vigodman President, Chief Executive Officer & Director
Yitzhak Peterburg Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL IN..-24.91%51 659
JOHNSON & JOHNSON16.06%322 232
ROCHE HOLDING LTD.-12.41%215 081
NOVARTIS AG-10.14%211 231
PFIZER INC.4.80%204 049
MERCK & CO., INC.18.46%171 858
More Results